新たな心血管疾患治療薬Obicetrapibの有効性が証明される 国際共同試験BROADWAYがObicetrapibの高リスク心血管疾患患者に対する安全性と有効性を確認。新薬の可能性に期待がかかる。

新たな心血管疾患治療薬Obicetrapibの有効性が証明される #Obicetrapib #心血管疾患 #BROADWAY試験

国際共同試験BROADWAYがObicetrapibの高リスク心血管疾患患者に対する安全性と有効性を確認。新薬の可能性に期待がかかる。

新たな脂質低下薬Obicetrapibの心血管疾患における効果実証！ 高リスク心血管疾患患者におけるObicetrapibの安全性と有効性を確認したBROADWAY試験について解説します。

新たな脂質低下薬Obicetrapibの心血管疾患における効果実証！ #大阪府 #枚方市 #Obicetrapib #BROADWAY試験 #LDL-C

高リスク心血管疾患患者におけるObicetrapibの安全性と有効性を確認したBROADWAY試験について解説します。

Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management Menarini Group's request to EMA for the registration of Obicetrapib aims to provide new treatment options for patients with primary hypercholesterolemia. This could potentially enhance cholesterol management in patients unable to achieve target levels.

Menarini Group Seeks EMA Approval for Obicetrapib Treatments for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment Menarini Group announces that EMA has accepted its applications for Obicetrapib and Obicetrapib/Ezetimibe to treat adults with primary hypercholesterolemia. This could revolutionize cholesterol management.

Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Cholesterol_Treatment

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management The European Medicines Agency has accepted the application for Obicetrapib and its combination with Ezetimibe, marking a potential breakthrough in managing high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib and its combination with Ezetimibe have been accepted for review by the EMA for treating patients with high cholesterol.

Menarini Group's Obicetrapib Receives EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment Menarini Group's Obicetrapib, a CETP inhibitor, receives EMA consideration to treat hypercholesterolemia, potentially helping patients not meeting LDL goals.

Menarini Group's Obicetrapib Gains EMA Review for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management Menarini Group's applications for Obicetrapib and Ezetimibe have been accepted for review by the EMA, offering new hope for cholesterol management.

Menarini Group's Obicetrapib and Ezetimibe Await EMA Approval for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management The European Medicines Agency has accepted Menarini's application for Obicetrapib, a potential first-in-class CETP inhibitor, aimed at improving cholesterol management in adults.

Menarini Group's Obicetrapib Receives EMA's Review for Cholesterol Management #Italy #Florence #Menarini_Group #Obicetrapib #CETP_inhibitor

Piramal Pharma and NewAmsterdam Pharma Enhance Production Capacity in Pennsylvania Piramal Pharma Solutions and NewAmsterdam Pharma are expanding their production capabilities for oral solid dosage forms at the Sellersville facility to meet growing demand.

Piramal Pharma and NewAmsterdam Pharma Enhance Production Capacity in Pennsylvania #USA #Obicetrapib #Piramal_Pharma #Sellersville #NewAmsterdam_Pharma

Piramal Pharma and NewAmsterdam Pharma Expand Oral Solid Dosage Capabilities in Pennsylvania Piramal Pharma Solutions and NewAmsterdam Pharma have invested in new facilities to enhance oral solid dosage production at the Sellersville site, benefiting patient care and local economy.

Piramal Pharma and NewAmsterdam Pharma Expand Oral Solid Dosage Capabilities in Pennsylvania #USA #Obicetrapib #Piramal_Pharma #Sellersville #NewAmsterdam_Pharma

Obicetrapib–ezetimibe combo reduces LDL in patients at high atherosclerosis risk Obicetrapib plus ezetimibe for 12 weeks reduced LDL cholesterol by almost 50% in people with or at high risk for atherosclerotic cardiovascular disease.

#MedNews - Obicetrapib plus #ezetimibe for 12 weeks reduced LDL cholesterol by almost 50% in people with or at high risk for #ASCVD.

Full story 👉 buff.ly/WFQx2Yx

#CardioSky #obicetrapib

Obicetrapib reduces LDL cholesterol by 30% in patients at high CV risk Adding obicetrapib to existing lipid-lowering therapy reduces LDL cholesterol levels by 30% in patients with atherosclerotic CV disease or heterozygous familial hypercholesterolemia.

#MedNews - Adding #obicetrapib to existing lipid-lowering therapy reduces LDL-C levels by 30% in patients with atherosclerotic #CVD or heterozygous familial hypercholesterolemia.

Full story 👉 buff.ly/eVAIhEG

#CardioSky #Cholesterol

This cholesterol pill may fight high risk of heart attack, stroke: Study - Yes Punjab News New study shows Obicetrapib significantly lowers LDL and Lp(a), offering hope to heart patients struggling to meet cholesterol targets despite current treatments.

This cholesterol pill may fight high risk of heart attack, stroke: Study yespunjab.com?p=121841

#Obicetrapib #HeartHealth #CholesterolTreatment #CardiovascularCare #LDL #LipoproteinA #HeartAttackPrevention #MonashStudy #MedicalBreakthrough #NEJM

Obicetrapib slashes LDL cholesterol by over 30% in high-risk heart patients A large multinational trial published in the New England Journal of Medicine shows that obicetrapib significantly lowers LDL cholesterol in high-risk cardiovascular patients. The CETP inhibitor also i...

Obicetrapib slashes LDL cholesterol by over 30% in high-risk heart patients 🫀💊🌍 www.news-medical.net/news/2025050... #Cardiology #LDL #Cholesterol #Obicetrapib #HeartHealth #ClinicalTrial #NEJM #LipidLowering @nejm.org

New drug could help people with a high heart risk to lower their cholesterol by 30% New drug could help people with a high heart risk to lower their cholesterol by 30% A trial of a newly developed drug, Obicetrapib, has found that it could reduce levels of 'bad cholesterol' by…

💊 A trial of a newly developed drug, #Obicetrapib, has found that it could reduce levels of 'bad cholesterol' by around 30% in people at high risk of cardiovascular events, says @monashuniversity.bsky.social

@eassociety.bsky.social #EASCongress2025 #lipids #obicetrapib

Menarini Group Reports Positive Phase-3 Results for Obicetrapib and Ezetimibe Combination Therapy Menarini Group announced positive topline results from its Phase-3 studies BROADWAY and TANDEM, investigating the LDL cholesterol-lowering efficacy of Obicetrapib.

Menarini Group Reports Positive Phase-3 Results for Obicetrapib and Ezetimibe Combination Therapy #USA #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Menarini Group Reports Positive Findings from Phase 3 Clinical Trials on Obicetrapib and Ezetimibe Combination Menarini Group recently announced encouraging outcomes from their Phase 3 BROADWAY and TANDEM trials emphasizing LDL-C reduction through Obicetrapib and Ezetimibe.

Menarini Group Reports Positive Findings from Phase 3 Clinical Trials on Obicetrapib and Ezetimibe Combination #Italy #Clinical_Trials #Florence #Menarini_Group #Obicetrapib

Menarini Group Reports Positive Phase 3 Trial Results for Obicetrapib in Lipid Management Menarini Group has announced favorable results from its Phase 3 BROADWAY and TANDEM clinical trials, focusing on the efficacy of obicetrapib in LDL cholesterol reduction.

Menarini Group Reports Positive Phase 3 Trial Results for Obicetrapib in Lipid Management #Italy #Florence #Menarini_Group #Obicetrapib #Ezetimibe

Menarini Group Reports Positive Results from Phase 3 Trials for Obicetrapib in Treating High Cholesterol Menarini Group recently announced encouraging results from Phase 3 trials, assessing Obicetrapib and its combination with Ezetimibe to lower LDL cholesterol effectively.

Menarini Group Reports Positive Results from Phase 3 Trials for Obicetrapib in Treating High Cholesterol #Italy #Clinical_Trials #Florence #Menarini_Group #Obicetrapib

Menarini Group Reports Exciting Results from Clinical Trials on New Heart Drug Obicetrapib Menarini Group unveils promising outcomes from the BROADWAY and TANDEM trials, showcasing Obicetrapib as a revolutionary treatment for LDL-C management.

Menarini Group Reports Exciting Results from Clinical Trials on New Heart Drug Obicetrapib #Italy #Clinical_Trials #Florence #Menarini_Group #Obicetrapib

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ... -- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at...

Top line results from TANDEM trial. The oral fixed dose combination pill of #obicetrapib + ezetimibe lowered LDL-C by 50% with >70% of patients achieving LDL-C <55 mg/dL. Very encouraging results while we await the CVOT of obicetrapib. #CardioSky #lipids

ir.newamsterdampharma.com/news-release...

#AHA24 Please stay around to this afternoon's late breaking clinical trial session on #lipids! Phase 2 data for 2 new #LPa therapeutics ( #zerlasiran & #muvalaplin)
and phase 3 data of #obicetrapib for LDL-C lowering in HeFH. #CardioSky @ahascience.bsky.social